Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.

Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101125969 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2008-2231 (Electronic) Linking ISSN: 15608115 NLM ISO Abbreviation: Daru Subsets: MEDLINE

Publication: 2018- : Cham : Springer International Publishing
Original Publication: Tehran, Iran : The Faculty

Anti-Bacterial Agents*/administration & dosage ; Anti-Bacterial Agents*/chemistry ; Drug Carriers*/administration & dosage ; Drug Carriers*/chemistry ; Drug Resistance, Multiple, Bacterial* ; Nanoparticles*/administration & dosage ; Nanoparticles*/chemistry; Animals ; Bacteria/drug effects ; Humans

Introduction: Infectious diseases associated with intracellular bacteria such as Staphylococcus aureus, Salmonella typhimurium and Mycobacterium tuberculosis are important public health concern. Emergence of multi and extensively drug-resistant bacterial strains have made it even more obstinate to offset such infections. Bacteria residing within intracellular compartments provide additional barriers to effective treatment.
Method: Information provided in this review has been collected by accessing various electronic databases including Google scholar, Web of science, Scopus, and Nature index. Search was performed using keywords nanoparticles, intracellular targeting, multidrug resistance, Staphylococcus aureus; Salmonella typhimurium; Mycobacterium tuberculosis. Information gathered was categorized into three major sections as 'Intracellular targeting of Staphylococcus aureus, Intracellular targeting of Salmonella typhimurium and Intracellular targeting of Mycobacterium tuberculosis' using variety of nanocarrier systems.
Results: Conventional management for infectious diseases typically comprises of long-term treatment with a combination of antibiotics, which may lead to side effects and decreased patient compliance. A wide range of multi-functionalized nanocarrier systems have been studied for delivery of drugs within cellular compartments where bacteria including Staphylococcus aureus, Salmonella typhimurium and Mycobacterium tuberculosis reside. Such carrier systems along with targeted delivery have been utilized for sustained and controlled delivery of drugs. These strategies have been found useful in overcoming the drawbacks of conventional treatments including multi-drug resistance.
Conclusion: Development of multi-functional nanocargoes encapsulating antibiotics that are proficient in targeting and releasing drug into infected reservoirs seems to be a promising strategy to circumvent the challenge of multidrug resistance. Graphical abstract.

Front Pharmacol. 2017 Sep 05;8:606. (PMID: 28928662)
Iran J Pharm Res. 2019 Winter;18(1):446-458. (PMID: 31089379)
Clin Infect Dis. 2009 Jan 1;48(1):1-12. (PMID: 19035777)
Emerg Infect Dis. 1998 Apr-Jun;4(2):195-209. (PMID: 9621190)
Infect Immun. 2008 Mar;76(3):907-15. (PMID: 18160481)
Ther Deliv. 2012 Aug;3(8):915-7. (PMID: 22946425)
Virulence. 2018 Jan 1;9(1):28-63. (PMID: 28960132)
Int J Nanomedicine. 2018 Nov 09;13:7333-7347. (PMID: 30519018)
Dev Comp Immunol. 2016 Jun;59:34-8. (PMID: 26778297)
Sci Rep. 2017 Jan 23;7:41104. (PMID: 28112240)
Int J Antimicrob Agents. 2011 Feb;37(2):140-4. (PMID: 21130608)
Materials (Basel). 2018 Feb 23;11(2):. (PMID: 29473883)
Genome Res. 2009 Dec;19(12):2279-87. (PMID: 19901036)
J Immunol. 1993 Apr 1;150(7):2920-30. (PMID: 8454864)
Int J Antimicrob Agents. 2000 Jan;13(3):155-68. (PMID: 10724019)
Nat Rev Microbiol. 2011 Mar;9(3):215-22. (PMID: 21297670)
AAPS PharmSciTech. 2012 Jun;13(2):411-21. (PMID: 22359159)
Vet World. 2019;12(4):504-521. (PMID: 31190705)
Allergy. 2019 Mar;74(3):560-571. (PMID: 30269350)
Mol Interv. 2006 Jun;6(3):124-30. (PMID: 16809472)
J Control Release. 2015 Aug 10;211:94-104. (PMID: 26055640)
Antimicrob Agents Chemother. 1989 Sep;33(9):1540-3. (PMID: 2684009)
Antimicrob Agents Chemother. 2000 Mar;44(3):533-9. (PMID: 10681314)
Mol Microbiol. 2005 May;56(3):811-23. (PMID: 15819634)
Nat Commun. 2015 May 11;6:7119. (PMID: 25960343)
Colloids Surf B Biointerfaces. 2017 Dec 1;160:40-47. (PMID: 28922635)
PLoS One. 2019 Feb 26;14(2):e0212858. (PMID: 30807612)
PLoS One. 2017 May 18;12(5):e0177987. (PMID: 28542623)
J Infect Chemother. 2014 Oct;20(10):593-601. (PMID: 25172776)
Infect Dis Clin North Am. 2016 Jun;30(2):377-390. (PMID: 27208764)
Biomaterials. 2016 Oct;104:43-51. (PMID: 27424215)
Sci Rep. 2019 May 27;9(1):7866. (PMID: 31133658)
Clin Exp Immunol. 2009 Aug;157(2):216-24. (PMID: 19604261)
Nature. 2015 Nov 19;527(7578):323-8. (PMID: 26536114)
Lancet Infect Dis. 2009 Jan;9(1):19-30. (PMID: 18990610)
J Immunol. 2001 Mar 1;166(5):3392-401. (PMID: 11207296)
Annu Rev Pathol. 2016 May 23;11:343-64. (PMID: 26925499)
Infect Immun. 2000 May;68(5):2671-84. (PMID: 10768959)
Clin Microbiol Rev. 2013 Apr;26(2):308-41. (PMID: 23554419)
J Antimicrob Chemother. 1996 Jan;37(1):105-15. (PMID: 8647751)
Annu Rev Biochem. 2009;78:119-46. (PMID: 19231985)
Science. 1994 Feb 4;263(5147):678-81. (PMID: 8303277)
Front Cell Infect Microbiol. 2012 Apr 24;2:43. (PMID: 22919634)
Science. 1985 Jul 19;229(4710):275-7. (PMID: 3160113)
Front Microbiol. 2017 Jul 19;8:1354. (PMID: 28769913)
FEBS J. 2010 Jun;277(11):2416-27. (PMID: 20553485)
Int J Pharm. 2004 Jan 9;269(1):37-49. (PMID: 14698575)
J Biomed Nanotechnol. 2013 Jun;9(6):1076-87. (PMID: 23858973)
ACS Nano. 2012 May 22;6(5):3820-31. (PMID: 22482704)
Int J Mol Sci. 2016 Nov 14;17(11):. (PMID: 27854260)
Infection. 1994 Sep-Oct;22(5):338-42. (PMID: 7843812)
Ann Intern Med. 1992 Aug 1;117(3):191-6. (PMID: 1352093)
Biochem J. 1985 Nov 15;232(1):1-14. (PMID: 2867759)
Pharm Res. 2001 Jul;18(7):1042-8. (PMID: 11496943)
Bioconjug Chem. 2014 Dec 17;25(12):2260-8. (PMID: 25394206)
Lancet. 1993 Mar 13;341(8846):647-50. (PMID: 8095569)
Sci Rep. 2016 Jan 05;6:18877. (PMID: 26728712)
Molecules. 2018 Apr 18;23(4):. (PMID: 29670009)
Adv Healthc Mater. 2018 Jun;7(12):e1701483. (PMID: 29696813)
Int J Biol Macromol. 2015 Mar;74:36-43. (PMID: 25475841)
Tuberc Res Treat. 2017;2017:4920209. (PMID: 28210505)
Med Clin North Am. 2007 Sep;91(5):863-70. (PMID: 17826106)
Pharm Res. 1994 Jan;11(1):38-46. (PMID: 8140054)
FASEB J. 2014 Dec;28(12):5071-82. (PMID: 25122556)
Eur J Pharm Biopharm. 2015 May;92:65-73. (PMID: 25701808)
ACS Nano. 2019 Apr 23;13(4):3992-4007. (PMID: 30822386)
J Biol Chem. 1982 Dec 25;257(24):14788-94. (PMID: 6294079)
Clin Microbiol Rev. 1999 Oct;12(4):564-82. (PMID: 10515903)
J Exp Med. 1997 Aug 18;186(4):569-80. (PMID: 9254655)
Front Microbiol. 2016 Nov 22;7:1827. (PMID: 27920756)
Int J Biol Macromol. 2012 Nov;51(4):392-9. (PMID: 22705573)
Lancet Infect Dis. 2011 Aug;11(8):595-603. (PMID: 21641281)
Clin Microbiol Rev. 2003 Jul;16(3):463-96. (PMID: 12857778)
Int J Pharm. 2007 Dec 10;345(1-2):154-62. (PMID: 17624699)
Front Immunol. 2018 Mar 01;9:396. (PMID: 29545804)
Glycobiology. 2017 Sep 1;27(9):861-867. (PMID: 28810659)
Proc Natl Acad Sci U S A. 1978 Jun;75(6):2959-63. (PMID: 208079)
J Infect Dis. 1972 May;125(5):486-90. (PMID: 5023643)
J Nanosci Nanotechnol. 2014 Jul;14(7):4745-56. (PMID: 24757944)
Front Pharmacol. 2019 Oct 04;10:1121. (PMID: 31636560)
J Infect Dis. 1983 Sep;148(3):563-70. (PMID: 6352828)
Cell Microbiol. 2009 Nov;11(11):1579-86. (PMID: 19775254)
mSphere. 2019 Jul 24;4(4):. (PMID: 31341073)
Eur J Pharm Biopharm. 2019 Mar;136:250-258. (PMID: 30685506)
PLoS Pathog. 2009 May;5(5):e1000451. (PMID: 19478870)
FEMS Microbiol Lett. 2012 Jul;332(1):1-9. (PMID: 22471308)
Antimicrob Agents Chemother. 2012 May;56(5):2259-67. (PMID: 22330919)
Curr Top Med Chem. 2017;17(18):2077-2099. (PMID: 28137237)
J Exp Med. 1952 Feb;95(2):209-30. (PMID: 14907971)
Int J Nanomedicine. 2011;6:3281-93. (PMID: 22228996)
AAPS PharmSciTech. 2019 Jan 9;20(2):67. (PMID: 30627867)
Semin Immunopathol. 2016 Mar;38(2):167-83. (PMID: 26510950)
J Appl Microbiol. 2019 Sep;127(3):701-712. (PMID: 31216601)
J Control Release. 2008 Apr 7;127(1):50-8. (PMID: 18230410)
Pharmaceutics. 2019 May 01;11(5):. (PMID: 31052403)
Clin Infect Dis. 2008 Jan 15;46(2):155-64. (PMID: 18171244)
Antimicrob Agents Chemother. 2012 May;56(5):2535-45. (PMID: 22354311)
Antimicrob Agents Chemother. 1998 Oct;42(10):2511-20. (PMID: 9756749)
Int J Pharm. 2018 Jan 30;536(1):50-62. (PMID: 29180254)
J Drug Target. 2011 Apr;19(3):219-27. (PMID: 20540651)
Virulence. 2017 Nov 17;8(8):1761-1775. (PMID: 28762868)
Nanomedicine. 2011 Jun;7(3):284-94. (PMID: 21059404)
J Biol Chem. 2013 Mar 8;288(10):6788-800. (PMID: 23306194)
Antimicrob Agents Chemother. 1978 Jun;13(6):1049-51. (PMID: 79336)
Int J Tuberc Lung Dis. 2009 May;13(5):569-73. (PMID: 19383188)

Keywords: Infectious disease; Intracellular targeting; Multidrug resistance; Mycobacterium tuberculosis; Salmonella typhimurium; Staphylococcus aureus

0 (Anti-Bacterial Agents)
0 (Drug Carriers)

Date Created: 20200321 Date Completed: 20210226 Latest Revision: 20210319

20250114

PMC7214552

10.1007/s40199-020-00337-w

32193748